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Objective: Assessing the frequency of Wearing-Off (WO) in Parkinson’s disease (PD) patients, and its
impact on Quality of Life (QoL).
Methods: Consecutive ambulatory patients, who were on dopaminergic treatment for 1 year, were
included in this multicentre, observational cross-sectional study. In a single visit, WO was diagnosed
based on neurologist assessment as well as using the validated Italian version of a patient self-rated 19-
question Wearing-Off Questionnaire (WOQ-19); WO was deﬁned for scores  2. QoL was evaluated by
the 8-item Parkinson’s Disease Questionnaire (PDQ-8).
Results: 617 subjectswere included,withameananti-Parkinson treatmentdurationof 6.6 4.6 years, 87.2%
were on levodopa treatment. Neurologists identiﬁed presence of WO in 351 subjects (56.9%), whereas 415
subjects (67.3%) were identiﬁed by the self-administered WOQ-19. In patients with a <2.5 years disease
duration,WOwasdiagnosed in12 subjects (21.8%)byneurologists and in23 subjects (41.8%)by theWOQ-19.
The most frequent WO symptoms, as identiﬁed by WOQ-19, were “slowness of movements” (55.8%) and
“reduced dexterity” (48.8%). Younger age, female gender, Uniﬁed Parkinson’s Disease Rating Scale (UPDRS)
part II score and duration of anti-Parkinson treatment were found signiﬁcantly associated with WO. The
numberofmotor (p< 0.0001) andnon-motor (p< 0.0001)WOsymptoms correlatedwithPDQ-8 total score.
Conclusions: WO is common already at the early stages of PD and is underestimated by routine neuro-
logical clinical evaluation. The number of WO symptoms, both motor and non motor, increases along
with disease duration and has a negative impact on patients QoL.
 2013 Elsevier Ltd. All rights reserved.a di Roma, Dipartimento di
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For over 40 years, levodopa has been the gold-standard of
treatment of PD, and patients unavoidably will require it during the
course of the disease. When patients are initially started on levo-
dopa therapy they experience a sustained clinical response
throughout the day. As the disease progresses, the therapeutic ef-
fect shortens and many patients experience beneﬁt only for a few
hours after ingestion of the drug: this step is otherwise known as
F. Stocchi et al. / Parkinsonism and Related Disorders 20 (2014) 204e211 205the WO. Despite several studies have been conducted in patients
with ﬂuctuations, it is difﬁcult to infer from the available data a
clear consensus on the prevalence, timing and characteristics of the
WO phenomenon. For many years, doctors considered the WO as a
late and even rare phenomenon. On the other hand, it is now
widely recognized that the development of WO has a signiﬁcant
impact on patient’s neurological disability and QoL [1e4].
The use of several patient self-assessed questionnaires proved to
be an effective tool in the diagnosis ofWO, showinghigher sensitivity
than the routine clinical evaluation [3,5,6]. Among them theWOQ-19
has recently been recognized by a task force of the Movement Dis-
orders Society as “recommendeddiagnostic screening tool in PD” [7].
The current studywas based on an observational, cross-sectional,
multicentre study called Early DEtection of wEaring off in Parkinson
disease (DEEP Study). The primary goal was to look at the frequency
of WO phenomena among a wide population of patients with PD,
and secondarily to assess the impact of WO on patient’s QoL.
2. Methods
2.1. Study design
The DEEP study included a preliminary phase, recently pub-
lished [8], that had as objective the linguistic and the psychometricTable 1
Demographic and clinical data of patients with and without WO, according to the WOQ-
Patients total (n ¼ 617) Patien
M:F (n) 381:236 244:1
Age, mean  SD (range) 66.8  9.2 (29.1e88.5) 65.9 
Disease duration, mean  SD (range) 8.0  4.7 (0.9e25.1) 8.97 
Disease duration, n (%)
<2.5 y 55 (8.9%) 23 (41
2.5-5 y 130 (21.1%) 71 (54
5e10 y 238 (38.6%) 165 (6
>10 y 194 (31.4%) 156 (8
H&Y staging, n (%)
Stage 1 60 (9.6%) 25 (41
Stage 1.5 88 (14.3%) 48 (54
Stage 2 220 (35.7%) 137 (6
Stage 2.5 139 (22.5%) 110 (7
Stage 3 88 (14.3%) 74 (84
Stage 4 20 (3.2%) 19 (95
Stage 5 2 (0.3%) 2 (100
UPDRS total score, mean  SD (range) 37.4  17.5 (5.0e111.0) 39.6 
Part I 2.2  1.9 (0e11) 2.3 
Part II 11.2  6.2 (0e35) 12.3 
Part III 24.0  11.7 (3e73) 25.1 
Anti-Parkinson therapy duration
(years), mean  SD (range)
6.6  4.6 (0e25) 7.4 
Levodopa therapy duration, (years),
mean  SD (range; n)
3.62  3.32 (0.22-23.39, n ¼ 525) 3.70 
Levodopa daily dosage, (mg),
mean  SD (range; n)
420.4  209.3 (50-1500; n ¼ 534) 439.4
Education (years), n
None 17 8
3-5 205 143
6-8 176 119
9-13 148 95
>13 71 50
Employment status, n (%)
employed 92 (14.9%) 65 (15
unemployed 107 (17.3%) 84 (20
retired 418 (67.7%) 266 (6
Caregiver assistance, n (%) 112 (18.2%) 92 (22
Smoking habits, n (%) 233 (38.5%) 154 (3
Alcohol consumption, n (%) 324 (54.5%) 209 (5
Physical activity, n (%) 195 (31.6%) 126 (3
MMSE 28.1  1.7 (24e30) 28.1 
Abbreviations: H&Y ¼ Hoehn & Yahr scale; UPDRS ¼ Uniﬁed Parkinson’s Disease Rating
*Shows statistically signiﬁcant p-values after Bonferroni’s correction (critical p-value ¼ 0validation as well as the diagnostic capacity assessment of the
Italian version of the WOQ-19. In this manuscript we present the
results of the core phase of the study, an epidemiological survey on
WO symptoms and their associated phenomena, in a population of
patients with PD.
From March to October 2010, we have prospectively recruited
patients with PD to participate in the DEEP study, conducted at 37
movement disorder clinics in Italy. A total of 634 patients were
evaluated, 207 have also participated to the WOQ-19 diagnostic
capacity study [8]. The inclusion criteriawere as follows: 1) age18
years; 2) a diagnosis of PD [9]; 3) levodopa and/or dopamine ago-
nists (DAs) therapy for 1 year before the study screening; 4)
ability to understand and ﬁll out theWOQ-19. The exclusion criteria
included the following: 1) a Mini-Mental State Examination
(MMSE) score  23 and/or a diagnosis of dementia according to
DSM-IV; 2) any severe disabling conditions adversely affecting the
patient’s mental status; 3) Deep Brain Stimulation treatment; 4)
any infusional therapy in the year before the study screening; 5)
current inclusion in other clinical trials.
Neurologists experienced in movement disorders collected,
following a speciﬁc training and during a single visit, standard
demographic and clinical information on all participants who met
the criteria, via a structured interview and by examination. This
included but was not limited to age, sex, educational level,19: the DEEP Study.
ts WOQ-19  2 (n ¼ 415) Patients WOQ < 2 (n ¼ 202) p value
71 137:65 0.0304
9.1 (29.1e87.3) 68.6  9.3 (31.4e88.5) 0.0005*
4.9 (0.9e25. 1) 6.21  3.9 (1.0e20.4) <0.001*
<0.001*
.8%) 32 (58.2%)
.6%) 59 (45.4%)
9.3%) 73 (30.7%)
0.4%) 38 (19.6%)
<0.0001*
.7%) 35 (58.3%)
.5%) 40 (45.4%)
2.3%) 83 (37.7%)
9.1%) 29 (20.8%)
.1%) 14 (15.9%)
.0%) 1 (5.0%)
%) 0 (0%)
18.1 (5.0e111.0) 32.8  15.4 (10.0e81.0) <0.0001*
2.1(0e11) 1.9  1.6 (0e6) 0.0087
6.3 (0e35) 9.1  5.2 (0e25) <0.0001*
12.3 (3e73) 21.6  10.1 (6e60) 0.0007*
4.8 (1e25) 4.8  3.7 (0e20) <0.0001*
3.58 (0.22-23.39; n ¼ 377) 3.42  2.55 (0.47-13.42; n ¼ 148) 0.3104
 217.0 (50-1500; n ¼ 386) 370.6  179.3 (100-1200; n ¼ 148) 0.0002*
0.3199
9
62
57
53
21
0.0105
.7%) 27 (13.4%)
.2%) 23 (11.4%)
4.1%) 202 (75.2%)
.2%) 20 (9.9%) 0.0002*
7.8%) 79 (39.9%) 0.6250
2.6%) 115 (58.4%) 0.1866
0.4%) 69 (34.1%) 0.6658
1.6 (24e30) 28.1  1.7 (24e30) 0.9507
Scale; MMSE ¼ Mini Mental State Examination.
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Fig. 1. Mean number of WO symptoms reported through the WOQ-19 by patients with
PD, stratiﬁed by disease duration: the DEEP study.
F. Stocchi et al. / Parkinsonism and Related Disorders 20 (2014) 204e211206employment status, need for care, life style habits. Speciﬁcally
disease related data were collected on age at disease onset, disease
duration, UPDRS scores, Hoehn & Yahr scale (H&Y), current and
previous therapy information, concomitant diseases. Cognitive
abilities and QoL were respectively investigated with the MMSE
and the 8-item Parkinson’s Disease Questionnaire (PDQ-8) [10].
2.2. Diagnosis of WO
The diagnosis of WO was made both on the neurologist evalu-
ation as well as on the basis of the patient self-assessment using the
Italian version of the WOQ-19. Neurologists used a trace of struc-
tured interview to patients, which investigated the periodic reap-
pearance of symptoms during the day, the temporal relationship
with the intake of at least one scheduled dose of medication in a
consistent and predictable modality, and the improvement after
intake of the drug. The interviewwas completed at discretion of the
neurologists and the ﬁnal diagnosis based on the overall impres-
sion. The WOQ-19 was ﬁlled in by participants in conjunction with
the visit, but neurologists were instructed to not interfere with the
compilation and were not aware of the questionnaire responses.
The questionnaire consists of 9 items assessing ﬂuctuations of
motor symptoms, including tremor, difﬁculty in speech, weakness,
problems with balance, slowness, reduced dexterity, general stiff-
ness, muscle cramps, difﬁculty getting out of the chair; and 10 items
assessing ﬂuctuations of non-motor symptoms, including anxiety,
sweating, mood changes, numbness, panic attacks, cloudy mind/
dullness of thinking, abdominal discomfort, experience hot and
cold, pain, aching [8]. For each item, patients were asked to tick
whether symptoms were present and whether they improved after
the following dose of anti-Parkinson treatment: a cutoff of 2
improved symptoms indicated diagnosis of WO [8].
2.3. Standard protocol approvals, registrations and patient consents
The study was approved by the Ethical Committees of each
participating institution and written informed consent and pro-
cessing personal data authorization were obtained from each
participant.
2.4. Statistical analysis
Descriptive analyses were mean and standard deviation (SD), or
median and interquartile range (IQR). Comparisons were per-
formed either by analysis of variance and Chi-square or Fisher exact
test. The signiﬁcance threshold was set to 0.05 with Bonferroni’s
correction in case of multiple comparisons.
In order to identify the variables associated with WO, logistic
regression analysis was performed, considering WOQ score 2 as
outcome of the dependent variable and as regressors: disease
duration, gender, age, education, UPDRS part I, II, III scores, treat-
ment duration, smoking habit, need for care (treatment duration
and dose were not considered for the model because available for a
lower portion of patients). The effect exerted by these variables on
QoL was also tested using linear models with PDQ8 as the contin-
uous dependent variable. Project management including data
banking, quality control and statistical analysis, was performed by
MEDIDATA (Modena, Italy).
3. Results
Of the 634 patients screened, 617 (97.3%) met the inclusion
criteria (Table 1); the excluded patients did not differ signiﬁcantly
on demographic and clinical parameters with respect to the study
population. Fifty hundred thirty eight (87.2%) patients were takinglevodopa, 64 (10.4%) as monotherapy, 465 (75.3%) were on DAs.
Additional medications were as follows: catechol O-methyl-
transferase (COMT) inhibitors in 211 (34.2%) subjects, MAO-B in-
hibitors in 241 (39.1%), anticholinergics in 22 (3.6%). Patients
receiving psychotropic drugs were 185 (30.0%). The most frequent
concomitant non-neurological disorders were: hypertension in
184 patients (29.8%), heart diseases in 75 (12.2%), diabetes in 54
(8.8%).3.1. Diagnosis of WO
Neurologists identiﬁed 351 subjects (56.9%) withWO symptoms
while 415 subjects (67.3%) were identiﬁed by the WOQ-19. The
WOQ-19 was more sensitive particularly in subjects with <2.5
years disease duration, with 23 (41.8%) patients indicating 2 WO
symptoms compared with 12 (21.8%) patients identiﬁed by neu-
rologists, similarly for subjects with 2.5e5 years (54.6% vs. 36.2%),
5e10 years (69.3% vs.60.1%), and >10 years disease duration (76.8%
vs. 80.4%; Fig. 1). For 489 (79.3%) patients there was agreement
between neurologists andWOQ-19 for the absence in 170 (27.6%) or
presence in 319 (51.7%) of WO. For 128 (20.8%) patients there was
disagreement; 32 (5.2%) those in whom WO diagnosis by neurol-
ogists was not conﬁrmed byWOQ-19, and 96 (15.6%) endorsed WO
symptoms through WOQ-19, which their neurologists did not di-
agnose. When considering levodopa therapy duration, among pa-
tients under treatment for 1 year, 61 (77.2%) were diagnosed as
having WO by WOQ-19 vs. 47 (59.5%) by neurologists, in subjects
treated for 1e2 years, 96 (75.6%) vs. 80 (63.0%), for 2e3 years 71
(66.4%) vs. 62 (57.9%), for 3e5 years 65 (66.3%) vs. 54 (55.1%), 84
(73.7%) vs. 85 (74.6%) subjects under levodopa treatment for >5
years.
Given the well-established reliability and higher sensitivity of
WOQ-19 in respect to the clinical evaluation, and considering also
the low degree of disagreement among subjects diagnosed by
neurologists and not through WOQ-19, from now on we will only
focus on the results based on WOQ-19 data. Overall, the mean
number of reported symptoms experienced in a normal day was
8.7  3.8, of which 5.6  2.1 were motor and 3.1  2.3 were non-
motor. Taking into account the symptoms reported as usually
improving after the following dose of anti-Parkinson medications
(otherwise deﬁned as WO symptoms) they were equal to a total of
4.1  3.8, 3.1  2.6 were motor and 1.0  1.6 were non motor. The
frequency of symptoms reported by patients through the WOQ-19
is listed in Table 2.
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Subjects with WO were signiﬁcantly younger (65.9  9.1 vs.
68.6 9.3 y; p¼ 0.0005). Patients withWO had signiﬁcantly longer
disease duration (8.974.9 vs. 6.213.9 y; p< 0.001), longer anti-
Parkinson treatment (7.4  4.8 vs. 4.8  3.7 y; p < 0.0001), greater
disability, as measured by the UPDRS total score (39.6  18.1 vs.
32.8  15.4; p < 0.0001), and greater disease severity, as measured
by the H&Y scale (p < 0.0001, Table 2), compared to subjects
without WO. Three hundred and ninety (94.0%) subjects diagnosed
with WO were being treated with levodopa, of whom 246 (84.8%)
in polytherapy, 6 (1.4%) were treated with DAs in monotherapy andTable 2
Frequency of experienced symptoms and WO symptoms, as reported by subjects, throug
Disease duration <2.5 years (n ¼ 55) 2.5e5.0 years (n ¼ 130)
Experienced and WO symptoms, n (%)
Tremor
Experienced 36 (65.5%) 93 (71.5%)
WO 18 (32.7%) 51 (39.2%)
Difﬁculty in speech
Experienced 18 (32.7%) 47 (36.2%)
WO 7 (12.7%) 22 (16.9%)
Weakness
Experienced 29 (52.7%) 91 (70.0%)
WO 7 (12.7%) 34 (26.2%)
Problems with balance
Experienced 22 (40.0%) 51 (39.2%)
WO 4 (7.3%) 21 (16.2%)
Slowness of movements
Experienced 43 (78.2%) 97 (74.6%)
WO 16 (29.1%) 53 (40.8%)
Reduced dexterity
Experienced 38 (69.1%) 83 (63.8%)
WO 13 (23.6%) 42 (32.3%)
General stiffness
Experienced 15 (27.3%) 56 (43.1%)
WO 4 (7.3%) 35 (26.9%)
Muscle cramps
Experienced 27 (49.1%) 66 (50.8%)
WO 4 (7.3%) 18 (13.8%)
Difﬁculty getting out of chair
Experienced 18 (32.7%) 42 (32.3%)
WO 2 (3.6%) 15 (11.5%)
Anxiety
Experienced 26 (47.3%) 65 (50.0%)
WO 8 (14.5%) 15 (11.5%)
Sweating
Experienced 11 (20.0%) 35 (26.9%)
WO 0 (0.0%) 7 (5.4%)
Mood changes
Experienced 22 (40.0%) 53 (40.8%)
WO 7 (12.7%) 13 (10.0%)
Numbness
Experienced 9 (16.4%) 21 (16.2%)
WO 1 (1.8%) 3 (2.3%)
Panic attacks
Experienced 3 (5.5%) 9 (6.9%)
WO 1 (1.8%) 1 (0.8%)
Cloudy mind
Experienced 8 (14.5%) 31 (23.8%)
WO 2 (3.6%) 5 (3.8%)
Abdominal discomfort
Experienced 13 (23.6%) 36 (27.7%)
WO 1 (1.8%) 2 (1.5%)
Feelings of hot/cold
Experienced 6 (10.9%) 21 (16.2%)
WO 1 (1.8%) 3 (2.3%)
Pain
Experienced 12 (21.8%) 43 (33.1%)
WO 0 (0.0%) 13 (10.0%)
Aching
Experienced 8 (14.5%) 37 (28.5%)
WO 2 (3.6%) 14 (10.8%)19 (4.6%) with DAs in association with MAO-B inhibitors. The
duration of treatment with levodopa did not differ between pa-
tients with and without WO (3.70  3.58 vs. 3.42  2.55;
p ¼ 0.3104), whilst the mean daily levodopa dosage was higher in
patients with WO (439.4  217.0 vs. 370.6  179.3; p ¼ 0.0002).
Regression logistic analysis found age, gender, UPDRS part II
score and duration of anti-Parkinson treatment signiﬁcantly asso-
ciated with WO. In details, every increase of one year of age was
associated with a 5.0% risk reduction of WO diagnosis (95% CI
0.928e0.973, p< 0.0001), while women showed a 80.1% higher risk
of experiencing WO than men (95% CI 1.134e2.861, p ¼ 0.0126).
Moreover, it has been calculated an increased risk of WO,h the WOQ-19, stratiﬁed by disease duration: the DEEP study.
5.0e10 years (n ¼ 238) >10 years (n ¼ 194) Total (n ¼ 617)
166 (69.7%) 131 (67.5%) 426 (69.0%)
119 (50.0%) 104 (53.6%) 292 (47.3%)
99 (41.6%) 115 (59.3%) 279 (45.2%)
38 (16.0%) 66 (34.0%) 133 (21.6%)
158 (66.4%) 155 (79.9%) 433 (70.2%)
83 (34.9%) 87 (44.8%) 211 (34.2%)
119 (50.0%) 127 (65.5%) 319 (51.7%)
52 (21.8%) 60 (30.9%) 137 (22.2%)
210 (88.2%) 174 (89.7%) 524 (84.9%)
141 (59.2%) 134 (69.1%) 344 (55.8%)
192 (80.7%) 170 (87.6%) 483 (78.3%)
124 (52.1%) 122 (62.9%) 301 (48.8%)
133 (55.9%) 133 (68.6%) 337 (54.6%)
94 (39.5%) 108 (55.7%) 241 (39.1%)
127 (53.4%) 111 (57.2%) 331 (53.6%)
39 (16.4%) 46 (23.7%) 107 (17.3%)
112 (47.1%) 123 (63.4%) 295 (47.8%)
59 (24.8%) 82 (42.3%) 158 (25.6%)
122 (51.3%) 113 (58.2%) 326 (52.8%)
46 (19.3%) 45 (23.2%) 114 (18.5%)
83 (34.9%) 104 (53.6%) 233 (37.8%)
15 (6.3%) 32 (16.5%) 54 (8.8%)
108 (45.4%) 98 (50.5%) 281 (45.5%)
46 (19.3%) 45 (23.2%) 111 (18.0%)
52 (21.8%) 53 (27.3%) 135 (21.9%)
15 (6.3%) 18 (9.3%) 37 (6.0%)
28 (11.8%) 33 (17.0%) 73 (11.8%)
7 (2.9%) 13 (6.7%) 22 (3.6%)
80 (33.6%) 75 (38.7%) 194 (31.4%)
29 (12.2%) 33 (17.0%) 69 (11.2%)
48 (20.2%) 53 (27.3%) 150 (24.3%)
11 (4.6%) 13 (6.7%) 27 (4.4%)
54 (22.7%) 50 (25.8%) 131 (21.2%)
11 (4.6%) 15 (7.7%) 30 (4.9%)
84 (35.3%) 64 (33.0%) 203 (32.9%)
21 (8.8%) 31 (16.0%) 65 (10.5%)
81 (34.0%) 74 (38.1%) 200 (32.4%)
30 (12.6%) 44 (22.7%) 90 (14.6%)
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score (95% CI 1.017e1.144, p ¼ 0.0117), and equal to 13.0% for each
additional year of anti-Parkinson treatment duration (95% CI
1.031e1.245, p ¼ 0.0094). The estimated risk for WO diagnosis
resulted unmodiﬁed even for ever tobacco smokers and alcohol
consumers.
3.3. WO and QoL
Subjects with WO reported worse Qol, as assessed by PDQ-8,
than subjects without WO (32.7  19.2 vs. 21.4  15.7,
p< 0.0001). The number of motor symptoms (0.34008; p< 0.0001)
as well as non-motor symptoms (0.33595; p < 0.0001) correlated
with PDQ-8 score. By linear regression analysis, the presence ofWO
symptoms, as identiﬁed byWOQ-19, corresponded to an increase of
1.15 points of the PDQ-8 score (p < 0.0001). Moreover, disease
severity assessed by H&Y scale (p ¼ 0.0003) and the need for
caregiver assistance (p < 0.0001) also showed a negative impact on
patient’s QoL.
4. Discussion
Our results indicate WO is a potentially “early” phenomenon, as
already 41.8% of the PD patients with <2.5 years disease duration
reported symptoms according to the WOQ-19 and 21.8% according
to neurologist assessment. The prevalence of WO was higher in
subjects with longer disease duration, and patients with >10 years
of disease durationwere diagnosed in 80.4% and 76.8% of the cases,
respectively by WOQ-19 and by neurologist assessments. As ex-
pected, the vast majority of patients with WO were on levodopa
(94%). Interestingly, the levodopa treatment duration did not
signiﬁcantly differ between patients with and without WO and
logistic regression analysis revealed that the time since initiation of
levodopa did not predict occurrence of WO. Similarly in a recent
observational study [12], even if frequency of WO symptoms
increased with the total duration of levodopa treatment, the
changes were minimal and 86.7% of patients treated for <1 year
with levodopa were rated as having WO based on WOQ-9 ques-
tionnaire vs. 89.5% for <5 years, and 92.7% for >5 years of levodopa
treatment.
This is a marked greater prevalence than previously estimated in
the literature. Older studies had showed that about 10% of patients
per year develop motor ﬂuctuations after initiation of treatment0 10 20 30 
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Fig. 2. Frequency of symptoms reported by patients through the WOQ-19: relative rates of
(yellow).with levodopa [13], and within 4e6 years of treatment up to 40% of
patients developWO [14], while almost all subjects would ﬂuctuate
after 10 years [1,15]. More recent studies are consisted with ours
and have documented that ﬂuctuations of parkinsonian features
may occur from the very early stages and WO symptoms can be
observed in patients a few months after the initiation of levodopa
treatment [16,17]. Up to 50% of patients experience motor ﬂuctu-
ations already by 2 years of treatment [18e20]. Our results conﬁrm
the ﬁnding of WO in a large percentage of patients with disease
duration of <2.5 years but clarify that manifestations are pre-
dominantly motor symptoms (Table 2).
Despite many studies have been conducted in PD patients with
ﬂuctuations, these differed in the deﬁnition of WO, heterogeneity
of study populations, different treatment regimens in accordance
with different standard of care that has changed over time. Most of
the data are extrapolated from interventional studies that may be
biased and probably are not representative of the overall popula-
tion of patients with PD; in these studies the identiﬁcation of WO
was usually not among the primary objectives and howsoever-
different assessment methodologies have been applied. Moreover,
the epidemiological data available to date have largely focused on
motor ﬂuctuations while non motor symptoms, difﬁcult to assess
but no less bothersome, have been often overlooked [3,21e24]. The
strengths of our results are the large population-based study,
focused to collect data about WO phenomenon and its related
manifestations in a large sample of clinically well-characterized
patients with PD, in standardized manner, using both clinical
assessment and the WOQ-19, which today represents one of the
most sensitive methods for WO screening. Assuming WO as
transverse phenomenon in the clinical course of PD, we chose an
observational design, including subjects under different treatments
at all stages of the disease, aiming to photograph the WO phe-
nomenon in a context of the current clinical practice. In addition,
our study has allowed to assess the impact of WO symptoms on
patient’s QoL.
Concerning clinical assessment, the rates of WO diagnosis per-
formed by our neurologists were generally higher compared to
other studies [12]. This could be due to heterogeneity of study
populations, or more likely because all our examining physicians
were movement disorders specialists, who had been speciﬁcally
trained with the task of completing a well-structured interview
focused to identify WO. Greater awareness and experience in col-
lecting data from patient medical history and asking the “right”40 50 60 70 80 90 
Frequency (%) 
subjects who experienced each symptom either as a WO manifestation (green) or not
F. Stocchi et al. / Parkinsonism and Related Disorders 20 (2014) 204e211 209questions can help make a more timely diagnosis of WO. In addi-
tion, patients ﬁlled-out the WOQ-19 just before being evaluated by
neurologists, and the order of these two diagnostic steps was not
randomized. A bias is plausible, as the patient after the completion
of the WOQ-19 could be more willing to report symptoms to the
neurologist, in this increasing the percentage of diagnosis of WO by
the neurologist.
For WO diagnosis through the WOQ-19 we arbitrarily adopted a
cut-off of at least two symptoms reported as ﬂuctuating along with
medication intake. This cut-off has been identiﬁed in the validation
study as the best compromise in sensitivity and speciﬁcity [8]. In
the present studyWOQ-19 datawere not analysed for different cut-
offs, and most likely higher values would be in better agreement
with the neurologist’s decision. Nevertheless, also our data showed
a marked discrepancy in perception between patients and neurol-
ogists, which has already been extensively discussed in previous
studies [6,12,25,26], and we agree that WO is potentially veriﬁable
at every stage of disease, and it is often underestimated by the
routine clinical assessment [4,12,15,16]. In our population, almost
three out of four WO manifestations were motor symptoms
(Table 2, Fig. 2), with slowness of movements (55.8%) and reduced
dexterity (48.8%) being the most common motor features, anxiety
(18.5%) and mood changes (18.0%) the most common non motor
features. Non-motor symptoms were generally less frequently
experienced, in proportion less frequently reported as ﬂuctuating
with treatment. The number ofWO symptoms, bothmotor and non
motor, increased in accordance with disease duration (Fig. 1,
Table 2), and correlated signiﬁcantly with QoL. Each additional
symptom indicated by patients through the WOQ-19 was associ-
ated with proportional worsening of the PDQ8 score. We found this
result interesting also because highlight that the WOQ-19 could be
potentially exploited not only in qualitative (diagnosis of WO), but
also in quantitative terms (number of symptoms). Future studies
could investigate the correlation between WOQ-19 and other
clinical features, in addition to QoL, and eventually validated as
measures of follow-up outcome.
In our cohort, patients with WO were signiﬁcantly younger and
the percentage of womenwas higher than in patients without WO.
Every additional year of age was associated with a 5.0% risk
reduction of WO, whilst female gender was associated with an
80.1% higher risk of WO. These ﬁndings are comparable to those
observed in a similar study, in which patients with WO wereAppendix 1. The Deep study group
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Leonardo Lopiano Neurologia 4 A.S.O. Molinettesigniﬁcantly younger and with a higher ratio of women, than those
without WO [5]. Conversely, in a British community-based study,
younger patients developed dyskinesias sooner than older patients,
but there was no correlation with motor ﬂuctuations, moreover
men and women did not differ in the occurrence of motor ﬂuctu-
ations or dyskinesias [1]. Thus, in a recent prospective study, female
gender was found associated with a shorter time to levodopa-
induced dyskinesias and younger age at diagnosis was reported
as associated with higher likelihood and shorter latency to develop
dyskinesias [27].
Our study has some limitations. This is a cross-sectional study
and potential risk factors for WO development and prognostic ef-
fect of different treatment choices were not assessed. The cohort
size of patients with short disease duration is small, perhaps
because the broad inclusion criteria have favoured the recruitment
of patients at more advanced stages. Therefore for statistical rea-
sons wewere forced us to gather data of patients into groups with a
relatively wide range of disease duration. Some important clinical
variables, such as treatment duration and dose were omitted from
the regression model analysis because only partially available.
Finally, through theWOQ-19 patients can only report the presence/
absence of ﬂuctuating symptom, but not the degree of severity.
Therefore, the information provided by the questionnaire is
nevertheless partial and still needs to be integratedwith the clinical
assessment.5. Conclusions
To our knowledge this is the largest epidemiological study tar-
geting the WO phenomenon as primary objective. Our results
indicatedWO as potentially observable across all disease stages and
that affect patient’s QoL. Since WO can be effectively treated by
changes in medication dose and kind its recognition is critical given
its negative implications on quality of life [28e30].Acknowledgements
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